Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Leukemia

• Publication date

  2018-10-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41375-018-0279-6PMID 30291336
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epigenetics in cancer stem cells

  2017cited by this paper
• CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors

  2017cited by this paper
• Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference

  2017cited by this paper
• The biomarkers of leukemia stem cells in acute myeloid leukemia.

  2017cited by this paper
• Diagnostic and Prognostic Value of CD123 in Acute Myeloid Leukemia (AML)

  2017cited by this paper
• CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection

  2017cited by this paper
• OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs

  2016cited by this paper
• Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

  2016cited by this paper
• Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia

  2016cited by this paper
• A 17-gene stemness score for rapid determination of risk in acute leukaemia

  2016cited by this paper
• Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones

  2016cited by this paper
• Abstract 2470: Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies

  2015cited by this paper
• Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences

  2015cited by this paper
• Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance.

  2015cited by this paper
• Targeting the canonical Wnt/β-catenin pathway in hematological malignancies

  2015cited by this paper
• Differential analyses for RNA-seq : transcript-level estimates improve gene-level inferences Supplementary Material

  2015cited by this paper
• Cancer stem cells – important players in tumor therapy resistance

  2014cited by this paper
• Epigenetic targeting of ovarian cancer stem cells.

  2014cited by this paper
• Identification of small molecules that support human leukemia stem cell activity ex vivo

  2014cited by this paper
• In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies

  2014cited by this paper
• BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

  2014cited by this paper
• Epigenetics of cancer stem cells: Pathways and therapeutics.

  2014cited by this paper
• AML drug resistance: c-Myc comes into play.

  2014cited by this paper
• Evolution of the cancer stem cell model.

  2014cited by this paper
• An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia

  2014cited by this paper
• Blockade of CD47‐mediated cathepsin S/protease‐activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma

  2014cited by this paper
• c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.

  2014cited by this paper
• Cancer stem cells: are they responsible for treatment failure?

  2014cited by this paper
• Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

  2014cited by this paper
• Self-renewal as a therapeutic target in human colorectal cancer

  2013cited by this paper
• Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.

  2012cited by this paper
• The role of epigenetic regulation in stem cell and cancer biology

  2012cited by this paper
• Cancer epigenetics: from mechanism to therapy.

  2012cited by this paper
• Epigenetic alterations involved in cancer stem cell reprogramming

  2012cited by this paper
• Recent advances in acute myeloid leukemia stem cell biology

  2012cited by this paper
• Resistance, epigenetics and the cancer ecosystem

  2011cited by this paper
• Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.

  2011cited by this paper
• High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study

  2011cited by this paper
• ConsensusPathDB: toward a more complete picture of cell biology

  2010cited by this paper
• The Class I Hdac Inhibitor Mgcd0103 Induces Cell Cycle Arrest and Apoptosis in Colon Cancer Initiating Cells by Upregulating Dickkopf-1 and Non-Canonical Wnt Signaling

  2010cited by this paper
• Drug combination studies and their synergy quantification using the Chou-Talalay method.

  2010cited by this paper
• The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

  2010cited by this paper
• Current and emerging therapies for acute myeloid leukemia.

  2009cited by this paper
• Cancer stem cell epigenetics and chemoresistance.

  2009cited by this paper
• Molecular targets for epigenetic therapy of cancer.

  2009cited by this paper
• Epigenetic signatures in stem cells and cancer stem cells.

  2009cited by this paper
• Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment

  2008cited by this paper
• ConsensusPathDB—a database for integrating human functional interaction networks

  2008cited by this paper
• The role of histone deacetylases (HDACs) in human cancer

  2007cited by this paper
• Epigenetics as a mechanism driving polygenic clinical drug resistance

  2006cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper

• The translational potential of epigenetic modulatory bioactive phytochemicals as adjuvant therapy against cancer.

  2025cites this paper
• Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study

  2025cites this paper
• Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors

  2024cites this paper
• Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.

  2024cites this paper
• FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology

  2024cites this paper
• RNA modification in normal hematopoiesis and hematologic malignancies

  2024cites this paper
• Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials

  2024cites this paper
• A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance

  2023cites this paper
• CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3‐ITD and DNM3TA‐R882 double mutations

  2023cites this paper
• Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.

  2023cites this paper
• Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

  2023cites this paper
• Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.

  2023cites this paper
• Quantitative Profiling of Alpha-Subunit of IL-3 Receptor on Single Acute Myeloid Leukemia Cells by Super-Resolution Imaging

  2023influential citation
• Pediatric acute myeloid leukemia: insight into genetic landscape and novel targeted approaches.

  2023cites this paper
• Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma

  2022cites this paper
• CD47 mediates the progression of colorectal cancer by inducing tumor cell apoptosis and angiogenesis.

  2022cites this paper
• RETRACTED ARTICLE: Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4

  2022cites this paper
• Updates of Role of Stem Cells in Cancer Therapy

  2022cites this paper
• Harnessing Apoptosis in AML.

  2021cites this paper
• Emerging Immunotherapy for Acute Myeloid Leukemia

  2021cites this paper
• GADD45g acts as a novel tumor suppressor and its activation confers new combination regimens for the treatment of AML.

  2021cites this paper
• Markers and Reporters to Reveal the Hierarchy in Heterogeneous Cancer Stem Cells

  2021cites this paper
• A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confers to suppression of acute myeloid leukemogenesis.

  2021cites this paper
• Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

  2021cites this paper
• SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells

  2021cites this paper
• Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma

  2021cites this paper
• Selective Inhibition of HDAC Class I Sensitizes Leukemia and Neuroblastoma Cells to Anticancer Drugs

  2021cites this paper
• Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia

  2021cites this paper
• Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity

  2021cites this paper
• Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance.

  2020cites this paper
• Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia

  2020cites this paper
• Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity

  2020cites this paper
• Histone Modifications in Stem Cell Development and Their Clinical Implications

  2020influential citation
• Regulating the Regulators: The Role of Histone Deacetylase 1 (HDAC1) in Erythropoiesis

  2020cites this paper
• Epigenetic Regulations of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway.

  2020cites this paper
• The potentials of immune checkpoints for the treatment of blood malignancies.

  2020cites this paper
• AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.

  2020influential citation
• Low frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia

  2020cites this paper
• Role of HDACs in normal and malignant hematopoiesis

  2020cites this paper
• The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia

  2019cites this paper
• HDAC Inhibitors in Acute Myeloid Leukemia

  2019cites this paper
• CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies

  2019cites this paper
• Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia

  2019cites this paper
• High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia

  2019cites this paper
• Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection

  2019cites this paper
• SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.

  2019cites this paper
• Mesenchymal Stem Cells and Cancer: Clinical Challenges and Opportunities

  2019cites this paper
• World Journal of Clinical Oncology

  year unknowncites this paper